Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

Arbutus gains in patent ruling against Moderna over COVID-19 vaccine By Investing.com

Natural Gas Inventory +95 bcf vs +88 bcf Expected By Investing.com

[the_ad id="21475"]

[ad_1]

WARMINSTER, Pa. – Arbutus Biopharma (NASDAQ:) Corporation (NASDAQ:ABUS), a company focused on finding a cure for chronic hepatitis B, has received a favorable ruling in a patent infringement lawsuit against Moderna (NASDAQ:), Inc. concerning technology used in Moderna’s COVID-19 vaccine, MRNA-1273.

The U.S. District Court for the District of Delaware has agreed with Arbutus and its licensee Genevant Sciences on key aspects of the patent claims in question. The court’s decision supports Arbutus’s interpretation of the disputed patent terms related to lipid nanoparticle (LNP) formulations that encapsulate mRNA, a crucial component of Moderna’s vaccine technology.

According to the court’s opinion, the patents covering the composition of total lipid, the cationic lipid with protonatable tertiary amine, and the encapsulation efficiency of mRNA, were upheld in favor of Arbutus’s claims.

The court validated the company’s position that the claimed molar percentage ranges of the composition can be met by any particle and are not limited to “finished” particles. Additionally, the court agreed that there is no limitation as to the molar percentage of the claimed cationic lipid and that the encapsulation efficiency terms are to be interpreted as Arbutus suggested.

Arbutus’s Interim President and CEO, Michael J. McElhaugh, expressed satisfaction with the court’s decision, highlighting the company’s commitment to defending its intellectual property. Arbutus and Genevant Sciences are seeking compensation from Moderna for the use of their patented LNP technology, which they claim was essential for the success of the COVID-19 vaccine.

The company’s broader focus remains on developing treatments for chronic hepatitis B virus (cHBV) infection, with a pipeline that includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101, both of which are in clinical trials.

The full details of the court’s claim construction ruling are available on the Arbutus website. The outcome of this case may have significant implications for the biopharmaceutical industry, particularly in the area of mRNA vaccine development. The information in this article is based on a press release statement issued by Arbutus Biopharma Corporation.

InvestingPro Insights

Following the favorable court ruling in its patent infringement lawsuit, Arbutus Biopharma Corporation’s (NASDAQ:ABUS) financial health and market performance provide additional context for investors. With a market…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]